bluebird bio Reports Fiscal Year End 2013 Financial Results
Published: Mar 06, 2014
bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and orphan diseases, today reported financial results and operational highlights for the fiscal year ended December 31, 2013. At fiscal year end bluebird bio held $206.3 million in cash and cash equivalents.
Help employers find you! Check out all the jobs and post your resume.